A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria
Open Access
- 1 August 2017
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 259, 83-91
Abstract
No abstract availableKeywords
Funding Information
- EPSRC (1367109)
- Leverhulme Trust (ECF/2015-075)
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (CE140100036)
This publication has 41 references indexed in Scilit:
- Structure–activity relationships for the binding of polymyxins with human α-1-acid glycoproteinBiochemical Pharmacology, 2012
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of PatientsAntimicrobial Agents and Chemotherapy, 2011
- Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patientsAnnals of Intensive Care, 2011
- Renal and neurological side effects of colistin in critically ill patientsAnnals of Intensive Care, 2011
- fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection modelsJournal of Antimicrobial Chemotherapy, 2010
- Colistin in the 21st centuryCurrent Opinion in Infectious Diseases, 2009
- Structure−Activity Relationships of Polymyxin AntibioticsJournal of Medicinal Chemistry, 2009
- Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical CenterClinical Infectious Diseases, 2009
- Polymyxins RevisitedClinical Microbiology Reviews, 2008
- Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006